Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Long-Term Deferred Tax (2018 - 2021)

Cytosorbents filings provide 3 years of Long-Term Deferred Tax readings, the most recent being $4.1 million for Q4 2021.

  • On a quarterly basis, Long-Term Deferred Tax rose 843.05% to $4.1 million in Q4 2021 year-over-year; TTM through Dec 2021 was $4.1 million, a 843.05% increase, with the full-year FY2021 number at $4.1 million, up 843.05% from a year prior.
  • Long-Term Deferred Tax hit $4.1 million in Q4 2021 for Cytosorbents, up from $431490.0 in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $4.1 million in Q4 2021 to a low of $21856.0 in Q4 2018.
  • Median Long-Term Deferred Tax over the past 3 years was $431490.0 (2020), compared with a mean of $1.5 million.
  • The widest YoY moves for Long-Term Deferred Tax: up 843.05% in 2021, down 843.05% in 2021.
  • Cytosorbents' Long-Term Deferred Tax stood at $21856.0 in 2018, then surged by 1874.24% to $431490.0 in 2020, then soared by 843.05% to $4.1 million in 2021.
  • The last three reported values for Long-Term Deferred Tax were $4.1 million (Q4 2021), $431490.0 (Q4 2020), and $21856.0 (Q4 2018) per Business Quant data.